Principal Financial Group
HRTX icon

Principal Financial Group’s Heron Therapeutics HRTX Stock Holding History

Principal Financial Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.15K Buy
+12,074
New +$9.68K ﹤0.01% 2154
2025
Q4 		– Sell
-11,654
Closed -$14.7K – 2222
2025
Q3 		$14.7K Sell
11,654
-68,630
-85% -$109K ﹤0.01% 2245
2025
Q2 		$166K Sell
80,284
-35,034
-30% -$71.5K ﹤0.01% 2146
2025
Q1 		$254K Buy
115,318
+1,758
+2% +$3.41K ﹤0.01% 2020
2024
Q4 		$174K Buy
113,560
+10,909
+11% +$17.7K ﹤0.01% 2118
2024
Q3 		$204K Buy
102,651
+84,205
+456% +$201K ﹤0.01% 2099
2024
Q2 		$64.6K Sell
18,446
-17,758
-49% -$54.6K ﹤0.01% 2260
2024
Q1 		$100K Sell
36,204
-704
-2% -$1.77K ﹤0.01% 2277
2023
Q4 		$62.7K Buy
36,908
+2,024
+6% +$2.23K ﹤0.01% 2315
2023
Q3 		$35.9K Buy
34,884
+1,190
+4% +$1.69K ﹤0.01% 2369
2023
Q2 		$39.1K Buy
33,694
+2,800
+9% +$4.99K ﹤0.01% 2376
2023
Q1 		$46.6K Sell
30,894
-2,199
-7% -$5.51K ﹤0.01% 2380
2022
Q4 		$82.7K Buy
33,093
+6,342
+24% +$20.4K ﹤0.01% 2326
2022
Q3 		$113K Sell
26,751
-634
-2% -$2.48K ﹤0.01% 2313
2022
Q2 		$76K Sell
27,385
-1,074
-4% -$4.31K ﹤0.01% 2426
2022
Q1 		$163K Buy
28,459
+553
+2% +$4.05K ﹤0.01% 2370
2021
Q4 		$254K Sell
27,906
-9,628
-26% -$98.3K ﹤0.01% 2291
2021
Q3 		$401K Buy
37,534
+1,663
+5% +$20.2K ﹤0.01% 2232
2021
Q2 		$556K Sell
35,871
-3,008
-8% -$47.9K ﹤0.01% 2191
2021
Q1 		$630K Sell
38,879
-2,074
-5% -$37K ﹤0.01% 2094
2020
Q4 		$867K Buy
40,953
+8,441
+26% +$147K ﹤0.01% 1972
2020
Q3 		$482K Sell
32,512
-1,186
-4% -$18.5K ﹤0.01% 2029
2020
Q2 		$496K Buy
33,698
+10,814
+47% +$178K ﹤0.01% 1972
2020
Q1 		$269K Buy
22,884
+1,572
+7% +$29.6K ﹤0.01% 1988
2019
Q4 		$501K Buy
21,312
+10,069
+90% +$223K ﹤0.01% 1948
2019
Q3 		$208K Buy
+11,243
New +$207K ﹤0.01% 2136
2019
Q2 		– Sell
-9,310
Closed -$228K – 2248
2019
Q1 		$228K Buy
9,310
+142
+2% +$3.72K ﹤0.01% 2098
2018
Q4 		$238K Sell
9,168
-3,041
-25% -$83.6K ﹤0.01% 2089
2018
Q3 		$386K Sell
12,209
-2,693
-18% -$100K ﹤0.01% 2017
2018
Q2 		$579K Buy
+14,902
New +$474K ﹤0.01% 1942

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Principal Financial Group's HRTX Position: Q2 2026 in Review

Principal Financial Group opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 12,074 shares worth $5.15K. The stake represents ﹤0.01% of the portfolio and ranks #2154 among its holdings. This is a return to the name: Principal Financial Group previously reported a position in HRTX as recently as Q3 2025.

Principal Financial Group first reported a position in HRTX in Q2 2018 and has held it in 30 quarters since. The position peaked at $867K in Q4 2020. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Principal Financial Group held 12,074 shares of Heron Therapeutics worth $5.15K as of Q2 2026.
  • Heron Therapeutics was a new Principal Financial Group position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2154 holding.
  • Principal Financial Group first reported a position in Heron Therapeutics in Q2 2018 and has held it in 30 quarters since.
  • Principal Financial Group's Heron Therapeutics position peaked at $867K in Q4 2020.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.